.png "back to home page")
FDA acts to expand use of treatment for COVID-19 patients with mild-to-moderate diseasehttps://t.co/P9YKgvdoWi
— #FlynnForTheWin ?????? (@BridgetKennyFl1) January 22, 2022
Hate to be or sound crude; they’ve had this on shelves for over a year;
Potentially;
while I almost died from Round 1;Alpha, #Omicron unless combined with flu? Cold!
Progress-FDA authorizes remdesivir outpatient #covid therapy @TuftsMedSchool @TuftsMedicalCtr @IDSAInfo @LevyCIMAR @McQHoya81 @CarlosdelRio7 @DrJeanneM @WinterCourseID @sanfordguide https://t.co/wALvK0GfHh
— Helen Boucher (@hboucher3) January 22, 2022
A seguir. Hi ha molta feina, encara
— Roger Paredes (@RutgerWalls) January 22, 2022
FDA approves use of antiviral drug remdesivir as an outpatient therapy for people with covid-19 - The Washington Post https://t.co/NkoOLnqMWX
Good - now let us quickly make hundreds of millions, if not billions, of doses for the world! https://t.co/L853KBpWBG
— Robert Hockett (@rch371) January 22, 2022
Remdesivir approved for outpatient use, 3x more effective than molnupravir.
— Michael Lin, MD PhD ? (@michaelzlin) January 22, 2022
BTW the recent results prove definitively that it works. Last year it was falsely described as ineffective in a badly designed open label WHO trial.
https://t.co/hHgN2glBf8
The drug can be administered at “skilled nursing facilities, home health-care settings and outpatient facilities such as infusion centers.” https://t.co/V6PyczdOKP
— Linda Hill (@bulldoghill) January 22, 2022
From @washingtonpost
— David Boulware, MD MPH (@boulware_dr) January 22, 2022
Boulware noted, however, that using <remdesivir> in an outpatient setting has logistical challenges.
“It is possible, but three daily infusions now make the one-time monoclonal antibody infusion seem simple,” Boulware said.https://t.co/YIarZJMm5s
"The Food and Drug Administration on Friday authorized the antiviral drug remdesivir as a treatment for some non-hospitalized adults and pediatric patients with mild to moderate COVID symptoms."https://t.co/RqypE5AbVM
— David Windt (@DavidLWindt) January 22, 2022
Do they care about public health even a little? https://t.co/KiXLZtHamI pic.twitter.com/rIa6prfQya
The FDA today authorized the antiviral drug remdesivir as a treatment for some non-hospitalized adults and pediatric patients with mild to moderate COVID symptoms.https://t.co/QPS0yLwjdT
— Axios (@axios) January 22, 2022
This is incontrovertible proof that @US_FDA only cares about pharma industry profits and not about health.
— Frank Ploegman (@FrankPloegman) January 22, 2022
Safe and highly effective off-patent (thus UNPROFITABLE) products are sabotaged.
Toxic, ineffective, highly PROFITABLE remdesivir is expanded.https://t.co/0HwvsPVBYq
Lunatic psychopaths.I guess the IFR numbers for Omicron were looking too favorable. https://t.co/Ixn5g5FKbk pic.twitter.com/YA4LgrSAJR
— Dr. Doug Corrigan (@ScienceWDrDoug) January 22, 2022